A Phase 2 interventional study of Dapagliflozin 10mg Tab and Placebo in Heart Failure and Acute Kidney Injury, sponsored by Yale University. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-13.
Sponsored by Yale University · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies testing dapagliflozin in Heart Failure — 15 open to participants now, 19 under way, 6 of them phase 3. dapagliflozin · Heart Failure.
Among the 59 studies testing dapagliflozin in Heart Failure, this one is the 21st largest by planned enrollment, is one of 3 that started in 2026, is one of 9 in phase 2, reaches primary completion later than 14 of the 18 other live ones, and was the 55th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →15 of the 59 studies testing dapagliflozin in Heart Failure are open now, in 12 countries. Recruiting first, the newest first:
The University of Hong Kong · Sites in Hong Kong
Ages 12+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+
AstraZeneca · Sites in United States, Argentina, Australia and 32 more countries
Ages 40+
University Medical Centre Ljubljana · Sites in Slovenia
Ages 18+
By country, each count listing its studies:
dapagliflozin: first FDA approval 2014 (FARXIGA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 14 · Phase 3 20 · Phase 4 22
First in 2015; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 130 is above the median of 76 across 4,053 interventional studies indexed under Heart Failure.
Median enrollment 100 across the 59 interventional studies. Of the 30 that completed or were terminated, 12 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 59 have an industry lead sponsor. The 10 most frequent:
Yale University is the lead sponsor of 1,773 studies on the registry; 298 are open to participants now.
Of its 221 completed or terminated interventional studies of FDA-regulated products, 129 (58%) have results posted.
33 studies in Heart Failure by Yale University: 9 open now, 12 under way, none of them phase 3. Of 20 finished, 8 (40%) have results posted.
Among the 33 studies in Heart Failure by Yale University, this one is the 11th largest by planned enrollment of the 27 interventional ones that give a count, is one of 4 that started in 2026, is one of 2 in phase 2, reaches primary completion later than 9 of the 11 other live ones, and was the 32nd registered.
Yale University’s Heart Failure studies by the year they started, since 2005.
4 of the studies testing dapagliflozin in Heart Failure that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06304857Phase 34th Military Clinical Hospital with Polyclinic, PolandCardioPROTECTion with Dapagliflozin in Breast Cancer Patients Treated with AnthrAcycline - PROTECTAA TRIAL | 2026-12-31 |
| NCT05374291Phase 3University Medical Center GroningenThe RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD | 2027-07 |
| NCT06578520Fundación para la Investigación del Hospital Clínico de ValenciaEffect of the Use of Dapagliflozin in Patients With Refractory Heart Failure | 2026-12-01 |
| NCT06762964Mayo ClinicCAMEO-FONTAN -Dapagliflozin in the Failing Fontan Circulation | 2027-02 |
Add all 4 to your calendar (.ics) → With an account.
Among the 59 studies testing dapagliflozin in Heart Failure, from their registry updates:
Among Yale University’s 33 in Heart Failure:
This tab as a report to print or save as PDF → With an account.
The overall objective of this study is to determine whether the addition of SGLT2 inhibitors to usual care in hospitalized patients with heart failure associated acute kidney injury is safe and efficacious. Investigators will assess if SGLT2 inhibition improves a composite cardio-renal outcome (mortality, dialysis, AKI progression, decongestion metrics, heart failure symptoms). Secondary objectives of this study are to compare individual components of the composite outcome as well as changes in biomarkers of kidney injury, inflammation, repair and oxidative stress between those exposed to the SGLT2 inhibitor vs placebo.
Individuals with heart failure are prone to acute kidney injury (AKI) as well as fluctuations in creatinine that meet AKI criteria. AKI diagnosis often complicates heart failure management and leads to interruptions of medications with long term benefit. AKI is also associated with long-term complications such as chronic kidney function and cardiovascular mortality. There is no efficient universal treatment for this type of AKI. In acute heart failure (AHF), although loop diuretics are the mainstay of treatment, diuretic resistance complicates the management. A drug that improves diuretic efficiency may lead to faster decongestion and improvement in kidney function.
Sodium-glucose co-transporter-2 inhibitors (SGLT2i) are drugs consistently shown to reduce hospitalizations in heart failure as well as progression of chronic kidney disease. They have also shown to promote kidney tubular health in pre-clinical models of kidney injury. They have been included in the armamentarium of heart failure care as goal directed medical therapy (GDMT) but concerns of efficacy and safety in patients with kidney dysfunction continue to limit their uptake and maintenance.
This study aims to promote increased use of SGLT2 inhibitors by demonstrating their safety and possible benefit in patients who develop kidney injury in the setting of heart failure to avoid interruptions in GDMT use.
To this end, 130 hospitalized adults with acute cardiorenal syndrome will be enrolled into a randomized controlled trial. Subjects will be randomized to receive either dapagliflozin or placebo for 14 days or until discharge (whichever comes first). Blood and urine samples will be collected for biomarker analysis, symptom and adverse event surveys will be administered, and various clinical parameters will be recorded on up to 6 study visits during hospitalization.
The primary outcome is a composite of short- and intermediate-term cardiorenal outcomes including: heart failure specific outcomes (objective measures of decongestion (i.e., effective diuresis), and a patient-reported outcome incorporating two dimensions of health state and a visual analogue scale (VAS)), kidney-specific outcomes (dialysis receipt, AKI progression to a higher stage, and change in serum creatinine), length of stay, and mortality. Secondary outcomes include trends in biomarkers of kidney injury, inflammation, oxidative stress, and repair, as well as individual components of the primary outcome as well as re-hospitalization rates.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects receive once daily 10 mg of oral dapagliflozin (Farxiga) for 14 days (or until discharge). Empaglifolozin may be used in case of dapagliflozin shortage.
Drug: Dapagliflozin 10mg Tab
Subjects receive once daily administration of a placebo comparator for 14 days (or until discharge).
Drug: Placebo
Administration of 10mg oral dapagliflozin once daily for 14 days (or until discharge).
Administration of placebo comparator once daily for 14 days (or until discharge).
Cardio-renal clinical improvement calculated as a Win Ratio
This outcome is assessed using a win ratio (total wins in the intervention group divided by total wins in the control group). Pairwise comparisons of predetermined components are made between each participant in the intervention and control group hierarchically in order of clinical importance, with a "win" assigned to the participant with the more favorable result at the first level of difference. The win ratio is the number of "winning" pairs for the treatment group divided by the number of "losing" pairs, with a win ratio greater than 1 indicating a benefit for the treatment.
Time frame: Calculated at 30 days post-randomization
Change in slope of serum creatinine over 14 days from enrollment
Measure of kidney function; assessed as a change in blood concentration.
Time frame: Measured at the time of enrollment (day 0) and on days 1-4, and day 14 +/- 4 days
Change in slope of serum cystatin-C over 14 days from enrollment
Measure of kidney function; assessed as a change in blood concentration.
Time frame: Measured at the time of enrollment (day 0) and on days 1-4, and day 14 +/- 4 days
Change in slope of serum serum NT-proBNP over 14 days from enrollment
Measure of kidney function; assessed as a change in blood concentration.
Time frame: Measured at the time of enrollment (day 0) and on days 1-4, and day 14 +/- 4 days
Change in slope of blood kidney injury molecule-1 (KIM-1) over 14 days from enrollment
Biomarker of renal tubular injury; assessed as a change in blood concentration.
Time frame: Measured at the time of enrollment (day 0) and on days 1-4, and day 14 +/- 4 days
Change in slope of urine kidney injury molecule-1 (KIM-1) over 14 days from enrollment
Biomarker of renal tubular injury; assessed as a change in urine concentration.
Time frame: Measured at the time of enrollment (day 0) and on days 1-4, and day 14 +/- 4 days
Change in slope of blood neutrophil gelatinase-associated lipocalin (NGAL) over 14 days from enrollment
Biomarker of renal tubular injury; assessed as a change in blood concentration.
Time frame: Measured at the time of enrollment (day 0) and on days 1-4, and day 14 +/- 4 days
Change in slope of urine neutrophil gelatinase-associated lipocalin (NGAL) over 14 days from enrollment
Biomarker of renal tubular injury; assessed as a change in urine concentration.
Time frame: Measured at the time of enrollment (day 0) and on days 1-4, and day 14 +/- 4 days
Change in slope of blood interleukin-6 (IL-6) over 14 days from enrollment
Biomarker of inflammation; assessed as a change in blood concentration.
Time frame: Measured at the time of enrollment (day 0) and on days 1-4, and day 14 +/- 4 days
Change in slope of urine interleukin-6 (IL-6) over 14 days from enrollment
Biomarker of inflammation; assessed as a change in urine concentration.
Time frame: Measured at the time of enrollment (day 0) and on days 1-4, and day 14 +/- 4 days
Change in slope of blood interluekin-18 (IL-18) over 14 days from enrollment
Biomarker of inflammation; assessed as a change in blood concentration.
Time frame: Measured at the time of enrollment (day 0) and on days 1-4, and day 14 +/- 4 days
Change in slope of urine interluekin-18 (IL-18) over 14 days from enrollment
Biomarker of inflammation; assessed as a change inurine concentration.
Time frame: Measured at the time of enrollment (day 0) and on days 1-4, and day 14 +/- 4 days
Change in slope of blood MPO over 14 days from enrollment
Biomarker of oxidative stress; assessed as a change in blood concentration.
Time frame: Measured at the time of enrollment (day 0) and on days 1-4, and day 14 +/- 4 days
Change in slope of urine MPO over 14 days from enrollment
Biomarker of oxidative stress; assessed as a change in urine concentration.
Time frame: Measured at the time of enrollment (day 0) and on days 1-4, and day 14 +/- 4 days
Change in slope of blood uromodulin (UMOD) over 14 days from enrollment
Biomarker of repair; assessed as a change in blood concentration.
Time frame: Measured at the time of enrollment (day 0) and on days 1-4, and day 14 +/- 4 days
Change in slope of urine uromodulin (UMOD) over 14 days from enrollment
Biomarker of repair; assessed as a change in urine concentration.
Time frame: Measured at the time of enrollment (day 0) and on days 1-4, and day 14 +/- 4 days
Change in slope of blood chitinase-3-like protein 1 (YKL-40) over 14 days from enrollment
Biomarker of repair. Assessed as a change in blood concentration.
Time frame: Measured at the time of enrollment (day 0) and on days 1-4, and day 14 +/- 4 days
Change in slope of urine chitinase-3-like protein 1 (YKL-40) over 14 days from enrollment
Biomarker of repair. Assessed as a change in urine concentration.
Time frame: Measured at the time of enrollment (day 0) and on days 1-4, and day 14 +/- 4 days
Change in slope of urine volume over 5 days from enrollment
Measure of decongestion; measured daily (i.e. every 24 hours) according to floor protocol.
Time frame: Measured at the time of enrollment (day 0) and on days 1-4 post-enrollment
Change in slope of weight over 14 days from enrollment
Measure of decongestion; assessed upon physical exam.
Time frame: Measured at the time of enrollment (day 0) and on days 1-4 and 14 post-enrollment
Change in slope of breathlessness score over 14 days from enrollment
Measure of decongestion using a survey, scored on a Likert scale from 1-5 (5 indicates more severe breathlessness).
Time frame: Measured at the time of enrollment (day 0) and on days 1-4, and day 14 post-enrollment
Change in slope of edema grade over 14 days from enrollment
Measure of decongestion; a score from 0 to 4+ is given on physical examination, with a higher score indicating higher edema.
Time frame: Measured at the time of enrollment (day 0) and on days 1-4, and day 14 post-enrollment
Change in slope of patient-reported edema over 14 days from enrollment
Measure of decongestion using a survey, scored on a Likert scale from 1-5 (5 indicates more severe edema).
Time frame: Measured at the time of enrollment (day 0) and on days 1-4, and day 14 post-enrollment
Change in slope of patient-reported VAS dyspnea score over 14 days from enrollment
A patient reported outcome measured on a visual analog scale of 1-100mm, with 100 indicating worse breathlessness.
Time frame: Measured at the time of enrollment (day 0) and on days 1-4, and day 14 post-enrollment
Cumulative Lasix equivalent diuretic dose over 5 days
Measure of decongestion
Time frame: Up to 5 days from enrollment
Proportion with kidney injury progression
Proportion with dialysis receipt or AKI progression to a higher stage up to 14 days from enrollment
Time frame: Up to 14 days post-enrollment
Percent survival at 30 days post-enrollment
Percent of subject's surviving to 30 days post-enrollment
Time frame: Up to 30 days post-enrollment
Percent of subjects re-hospitalized with heart failure and AKI at 30 days post-enrollment
Percent of rehospitalization up to 30 days post-enrollment
Time frame: Up to 30 days post-enrollment
Proportion with prescription of SGLT2i
Proportion with prescription of SGLT2i by subject's own provider
Time frame: Up to 30 days post-enrollment
Incidence of adverse events during exposure
Number of adverse events experienced by subjects, including sodium or potassium derangements, metabolic acidosis, urinary tract infections, fungal genitourinary infection, hypotension, allergic reactions, and hypoglycemia
Time frame: Up to 14 days post-enrollment or until hospital discharge
Change in heart failure symptoms (mobility and self care)
Change in score using a full and modified version of the EQ-5D-5L-VAS. The full questionnaire contains 5 dimensions of state of health and the VAS (visual analog scale) addressing perceived overall health and will be conducted on day 0 and 14. The modified version contains two dimensions of health (self care and mobility) and the VAS scale, and will be conducted on days 1, 2, 3, and 4. The EQ-5D-5L dimensions are scored on a Likert Scale from 1-5, with 5 indicating worsening health. The VAS is scored on a scale of 1 to 100, with 100 indicating better perceived overall health.
Time frame: Measured on Days 0, 1, 2, 3, 4, and 14 post-enrollment
Plan to share: Yes — De-identified data for the primary and secondary outcomes will be made available.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Upon publication; indefinitely.
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Aug 2028, 29 months after the start.
Of 111 non-industry phase 2 interventional studies under Heart Failure, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 66. This study's planned 29 months is below that.
Counting every sponsor, half of 185 studies reached it within 29 months; a quarter within 17 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dapagliflozin